Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

U.S. National Cancer Institute

PharmaDeviceNews U.S. National Cancer Institute

Representative image illustrating leukemia treatment research as Oryzon Genomics reports a 95% response rate with its experimental iadademstat combination in an early-stage acute myeloid leukemia trial.

Pharma & Biotech

Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development

by Soujanya Ravi
November 4, 2026
0 Comments

Oryzon Genomics reports a 95% AML response rate with iadademstat. See the remission findings, survival data and plans for Phase 3 trials.

Read More

Latest news and features

Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development
FDA grants breakthrough designation to daridorexant following 50-minute sleep improvement in children
Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research
Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results
Kairos Pharma highlights 17.7-month progression-free survival with ENV-105 combination in metastatic prostate cancer
Bayer’s asundexian cut recurrent stroke risk by 26%, but can new AHA evidence strengthen its global approval prospects?
Imperative Care reports comparable 30-day outcomes for women and men in 106-patient pulmonary embolism analysis
EVX-01 personalized cancer vaccine moves into focus as Evaxion examines broader immune responses
PAS-004 advances toward Phase 2 as Pasithea seeks new treatment approach for cutaneous neurofibromas
T-Cypher Bio reports promising cancer cell killing with two next-generation T-cell engagers.
Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns
Guardian Pharmacy Services has made another Tennessee acquisition, but can its local-first model sustain national growth?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

Vishay Intertechnology posts record $979m revenue as semiconductor demand drives margin recovery
Pfizer raises revenue outlook to $64bn as non-COVID medicines grow 7%
Pioneer Credit acquires A$206m debt portfolio for A$14.4m under new major bank agreement
Eaton sales jump 28% to $8.95bn as electrical backlog rises 46%
Uber bookings reach $59.8bn, but robotaxi spending and driver shortages test growth

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.